In the aftermath of announcing a major collaboration with Sandoz on biosimilars, Evotec’s chief business officer Matthias Evers speaks to Generics Bulletin about how the deal provides “validation” of Just-Evotec’s technology platform, while also outlining the firm’s wider ambitions to enable more efficient development of and broader access to biologics.
Matthias Evers is Evotec’s chief business officer • Source: Evotec
In a major deal for the off-patent industry, Sandoz recently announced a multi-year collaboration with Evotec subsidiary Just-Evotec Biologics that will see the firms develop and manufacture multiple biosimilars together.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
